pipeline overview

Our Avacc® vaccines pipeline

Intravacc is developing several innovative proprietary vaccines under the name Avacc. Each vaccine candidate is based on one of our platform technologies and the products are in various stages of development.

All of our products are available for licensing or partnering. If you are interested, our team is happy to discuss all possibilities with you.

Contact us

Our unique pipeline of Avacc® vaccine candidates, open for licensing

pipeline tabelle
Avacc2 news

Avacc® 2

A first-in-class prophylactic quadrivalent vaccine against hand, foot, and mouth disease (HFMD).

Download Vaccsheet Avacc  2

Avacc 3® 

Intravacc’s vaccine candidate against Pertussis, based on our proprietary OMV based platform.

Download Vaccsheet Avacc 3

Avacc3 news
Avacc5 news

Avacc® 5 

A first-in-class inactivated-virus vaccine against enterovirus D68.

Download Vaccsheet Avacc 5

Avacc® 10

An intranasal vaccine against COVID-19 based on Neisseria meningitidis Outer Membrane Vesicles mixed with stabilized spike protein.

Download Vaccsheet Avacc 10

Avacc11 news

Avacc® 11

A first-in-class vaccine against gonorrhea based on Neisseria gonorrhoeae outer membrane vesicles and encapsulated IL-12.

Download Vaccsheet Avacc 11

Avacc® 12

A vaccine against gonorrhea based on Neisseria meningitidis Outer Membrane Vesicles expressing N. gonorrhoeae antigens.

Download Vaccsheet Avacc 12

Avacc® 13

An outer membrane vesicle vaccine protecting against Neisseria meningitidis serogroup B.

Download Vaccsheet Avacc 13


Avacc® 31

A peptide-based conjugate vaccine targeting a neurotoxic dipeptide repeat protein found in patients with C9orf72 amyotrophic lateral sclerosis (C9-ALS).

Download Vaccsheet Avacc 31

Avacc31 news

Contact us

You can send us an email:

Reach out to Business Development: 

Or pick up the phone: 
+31 30 792 03 00

You can also just fill out the contact form on the right.

We look forward to hearing from you!


Contact form

Subscribe to our newsletter